Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IBI3032 · 1 trial · 1 indication
A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module
A summary of other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
An adverse event (AE) is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.
| Arm | Type | Description |
|---|---|---|
| Single dose4 of IBI3032 administered orally. | EXPERIMENTAL | dose4 IBI3032 |
| Single dose3 of IBI3032 administered orally. | EXPERIMENTAL | dose3 IBI3032 |
| Single dose4 of placebo administered orally. | PLACEBO_COMPARATOR | dose4 placebo |
| Single dose1 of IBI3032 administered orally. | EXPERIMENTAL | dose1 IBI3032 |
| Single dose3 of placebo administered orally. | PLACEBO_COMPARATOR | dose3 placebo |
| Single dose1 of placebo administered orally. | PLACEBO_COMPARATOR | dose1 placebo |
| Single dose2 of IBI3032 administered orally. | EXPERIMENTAL | dose2 IBI3032 |
| Single dose2 of placebo administered orally. | PLACEBO_COMPARATOR | dose2 placebo |
| Name | Type | Description |
|---|---|---|
| IBI3032 | DRUG | IBI3032: Method of administration: oral, fasted administration. |
| placebo | DRUG | Placebo (without active ingredients) Method of administration: oral, fasted administration. |
Inclusion Criteria: * Healthy male or females, as determined by medical history * Have safety laboratory results within normal reference ranges Exclusion Criteria: * Have known allergies toIBI3032， glucagon-like peptide-1 (GLP-1) analogs, related compounds * Abnormal electrocardiogram (ECG) at sc...
IBI3032 is an investigational small molecule being studied in healthy participants. It is currently in Phase 1 clinical development, with an ongoing trial evaluating its safety and tolerability. The drug is not approved for any medical condition and is being tested in a research setting.
IBI3032 is being developed by BrainsWay Ltd., a company traded on the stock exchange under the ticker BWAY. The company is conducting a Phase 1 clinical trial of IBI3032 in healthy volunteers in the United States.
IBI3032 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The current Phase 1 trial is recruiting participants and is designed to assess the drug's safety and tolerability in healthy individuals.
IBI3032 is being studied in a Phase 1 clinical trial with the identifier NCT07120425, titled 'A Study of IBI3032 in Healthy Participants.' This randomized, double-blind, placebo-controlled trial is recruiting 32 healthy adults aged 18 years and older in the United States.
No, IBI3032 is not FDA approved. It is an investigational drug currently in Phase 1 clinical trials. The ongoing study is evaluating its safety and tolerability in healthy participants, and it has not yet been approved for any medical use.